PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.

Abstract The inhibitory activities of docetaxel at a wide range of doses (0.1-10 mg/kg; subcutaneously (s.c.), once/week) in nude mice bearing a human prostate cancer cell (DU145), xenograft model with implantation of DU145 cells or a DU145 solid tumor were examined. This systematic trial demonstrated that (i) docetaxel was more effective in the xenograft model formed by implantation of DU145 cells than in the solid DU145 tumor; (ii) administration of 2.5 mg/kg docetaxel was the critical dose because inhibitory activities were not observed at 2.5 mg/kg, while they were noted at 5 mg/kg and 10 mg/kg in both implantation approaches; (iii) edema-like effects (plump body shape and legs) were observed in both groups at 2.5 mg/kg and the tumor sizes, often increased by blood plasma and other fluids, as well as body weights were higher than at other doses; and (iv) suppression of body weight gain was observed at 10 mg/kg docetaxel.
PMID
Related Publications

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.

Authors

Mayor MeshTerms
Keywords

DU145

Docetaxel

anti-cancer drug

dose-dependency

nude mice

side-effects

xenograft model

Journal Title anticancer research
Publication Year Start




PMID- 28373427
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145
      Xenograft Model.
PG  - 1665-1676
AB  - The inhibitory activities of docetaxel at a wide range of doses (0.1-10 mg/kg;
      subcutaneously (s.c.), once/week) in nude mice bearing a human prostate cancer
      cell (DU145), xenograft model with implantation of DU145 cells or a DU145 solid
      tumor were examined. This systematic trial demonstrated that (i) docetaxel was
      more effective in the xenograft model formed by implantation of DU145 cells than 
      in the solid DU145 tumor; (ii) administration of 2.5 mg/kg docetaxel was the
      critical dose because inhibitory activities were not observed at 2.5 mg/kg, while
      they were noted at 5 mg/kg and 10 mg/kg in both implantation approaches; (iii)
      edema-like effects (plump body shape and legs) were observed in both groups at
      2.5 mg/kg and the tumor sizes, often increased by blood plasma and other fluids, 
      as well as body weights were higher than at other doses; and (iv) suppression of 
      body weight gain was observed at 10 mg/kg docetaxel.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Mabuchi, Miyuki
AU  - Mabuchi M
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Ueda, Masahiro
AU  - Ueda M
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Yoshida, Yuri
AU  - Yoshida Y
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Horiike, Kota
AU  - Horiike K
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Yamaoka, Kenta
AU  - Yamaoka K
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Nakao, Syuhei
AU  - Nakao S
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Shimizu, Tadashi
AU  - Shimizu T
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
FAU - Ueda, Yuko
AU  - Ueda Y
AD  - Laboratory of Molecular and Cellular Physiology, Graduate School of
      Pharmaceutical Sciences, Osaka University, Suita, Japan.
FAU - Tsujikawa, Kazutake
AU  - Tsujikawa K
AD  - Laboratory of Molecular and Cellular Physiology, Graduate School of
      Pharmaceutical Sciences, Osaka University, Suita, Japan.
FAU - Tanaka, Akito
AU  - Tanaka A
AD  - School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan
      [email protected]
AD  - Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo
      University of Health Sciences, Kobe, Japan.
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (docetaxel)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Prostatic Neoplasms/*drug therapy/*pathology
MH  - Taxoids/*pharmacology
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - *DU145
OT  - *Docetaxel
OT  - *anti-cancer drug
OT  - *dose-dependency
OT  - *nude mice
OT  - *side-effects
OT  - *xenograft model
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/24 [received]
PHST- 2017/03/14 [revised]
PHST- 2017/03/15 [accepted]
AID - 37/4/1665 [pii]
AID - 10.21873/anticanres.11496 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1665-1676.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>